Holzer & Holzer LLC

Recent News

  • SHAREHOLDER ALERT: Investigation of Compass Minerals (CMP) Announced by Holzer & Holzer, LLC

    Atlanta, Georgia--(Newsfile Corp. - September 29, 2022) - Holzer & Holzer, LLC is investigating whether Compass Minerals International, Inc. ("Compass Minerals" or the "Company") (NYSE: CMP) complied with federal securities laws. On September 23, 2022, the SEC announced it had settled charges against Compass Minerals for "misleading investors" about a technology upgrade that had increased costs at the Company's most significant mine, despite representations the upgrade would create a cost savings. After this announcement, the Company's stock price...

    2022-09-29 5:52 PM EDT
  • SHAREHOLDER ALERT: Investigation of Avidity (RNA) Announced by Holzer & Holzer, LLC

    Atlanta, Georgia--(Newsfile Corp. - September 29, 2022) - Holzer & Holzer, LLC is investigating whether Avidity Biosciences, Inc. ("Avidity" or the "Company") (NASDAQ: RNA) complied with federal securities laws. On September 27, 2022, Avidity announced that the U.S. Food and Drug Administration has placed a partial clinical hold on new participant enrollment in its Phase 1/2 MARINA clinical trial following a serious adverse event. After this announcement, the Company's stock price dropped.If you purchased Avidity stock and suffered a loss on...

    2022-09-29 2:45 PM EDT
  • SHAREHOLDER ALERT: Holzer & Holzer Announces a Class Action Was Filed on Behalf of Centessa (CNTA) Investors and Encourages Investors With Significant Losses to Contact the Firm

    Atlanta, Georgia--(Newsfile Corp. - September 29, 2022) - Holzer & Holzer, LLC informs investors that a class action lawsuit was filed against Centessa Pharmaceuticals plc ("Centessa" or the "Company") (NASDAQ: CNTA). The lawsuit alleges Centessa negligently prepared its Offering Documents in connection with its initial public offering ("IPO") and made materially false and misleading statements and/or failed to disclose material adverse facts about the Company's business, operations, and prospects, including: (1) Centessa's treatment, lixivaptan, was less safe than Defendants had...

    2022-09-29 1:00 PM EDT
  • SHAREHOLDER ALERT: Holzer & Holzer Announces a Class Action Was Filed on Behalf of Olo (OLO) Investors and Encourages Investors With Significant Losses to Contact the Firm

    Atlanta, Georgia--(Newsfile Corp. - September 27, 2022) - Holzer & Holzer, LLC informs investors that a class action lawsuit was filed against Olo Inc. ("Olo" or the "Company") (NYSE: OLO). The lawsuit alleges Olo made materially false and misleading statements and/or failed to disclose material adverse facts about the Company's business, operations, and prospects, including: (1) Subway was ending its contract with Olo; and (2) Olo's key business metric - active locations - could not continue to grow as Defendants...

    2022-09-27 3:41 PM EDT
  • SHAREHOLDER ALERT: Investigation of BRP Group (BRP) Announced by Holzer & Holzer, LLC

    Atlanta, Georgia--(Newsfile Corp. - September 23, 2022) - Holzer & Holzer, LLC is investigating whether BRP Group, Inc. ("BRP Group" or the "Company") (NASDAQ: BRP) complied with federal securities laws. On September 13, 2022, NINGI Research issued a report alleging that BRP Group "has doctored its organic growth rate to beat analysts' estimates" and mislead investors "by presenting inorganic revenue as organic revenue through a self-proclaimed separate agreement with an affiliate." Following this report, the Company's stock price dropped.If you...

    2022-09-23 4:03 PM EDT
  • SHAREHOLDER ALERT: Holzer & Holzer Announces a Class Action Was Filed on Behalf of Humanigen (HGEN) Investors and Encourages Investors With Significant Losses to Contact the Firm

    Atlanta, Georgia--(Newsfile Corp. - September 22, 2022) - Holzer & Holzer, LLC informs investors that a class action lawsuit was filed against Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: HGEN). The lawsuit alleges Humanigen made materially false and misleading statements and/or failed to disclose that: (1) its product, lenzilumab, was less effective in treating hospitalized COVID-19 patients than the Company had represented; (2) as a result, the FDA was unlikely to approve an emergency use authorization for lenzilumab and the...

    2022-09-22 3:27 PM EDT
  • SHAREHOLDER ALERT: Investigation of Sotera Health (SHC) Announced by Holzer & Holzer, LLC

    Atlanta, Georgia--(Newsfile Corp. - September 22, 2022) - Holzer & Holzer, LLC is investigating whether Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ: SHC) complied with federal securities laws. On September 19, 2022, The Chicago Sun-Times reported that a jury found Sotera Health's Sterigenics business unit liable for a role in causing a woman's breast cancer due to its release of emissions from the Company's plant and awarded the plaintiff $363 million. Following this revelation, the Company's stock price...

    2022-09-22 2:49 PM EDT
  • SHAREHOLDER ALERT: Investigation of WalkMe (WKME) Announced by Holzer & Holzer, LLC

    Atlanta, Georgia--(Newsfile Corp. - September 22, 2022) - Holzer & Holzer, LLC is investigating whether WalkMe Ltd. ("WalkMe" or the "Company") (NASDAQ: WKME) complied with federal securities laws. On September 12, 2022, WalkMe announced "the departure of Chief Financial Officer, Andrew Casey," stating that he was leaving to pursue another opportunity. Following this news, the Company's stock price dropped.If you purchased WalkMe stock and suffered a loss on that investment, you are encouraged to contact Marshall Dees, Esq. at  mdees@holzerlaw.com  or Joshua...

    2022-09-22 2:47 PM EDT